Is Pramodini Medicare the Best Stock in Its Sector? A Look at the Numbers

Is Pramodini Medicare the best stock in its sector? The stock trades on the NSE at Rs 115 as of 21 October 2026, within its 52-week range of Rs 109.50 to Rs 137.00. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Pramodini Medicare

Pramodini Medicare Ltd is a diagnostic service provider offering technology-enabled diagnostic services across radiology, clinical laboratory and nuclear medicine, and company information says it was incorporated in 2000. It is an integrated diagnostic healthcare provider that also offers teleradiology. Its customers include government and private hospitals, medical colleges, PSUs and direct patients, served through hospital partnerships and standalone diagnostic centres. At a market capitalisation of Rs 254 Cr, it is tracked as part of the Diagnostics and Healthcare sector on Univest.

Is Pramodini Medicare the Best Stock in Its Sector?

Pramodini Medicare makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Pramodini Medicare's 14.61x P/E is below the 59.59x Industry P/E, Dr Lal PathLabs at 59.51x and Thyrocare Technologies at 44.76x, while its 32.69% ROE is higher than Dr Lal PathLabs at 20.13% and Thyrocare Technologies at 27.85%, and its debt to equity ratio of 0.34 is above Dr Lal PathLabs at 0.08 and Thyrocare Technologies at 0.09.

Metric	Pramodini Medicare
CMP (NSE)	Rs 115.10
52-Week High / Low	Rs 137.00 / Rs 109.50
Market Cap	Rs 254 Cr
P/E (TTM) vs Industry P/E	14.61x vs 59.59x
P/B	2.18
ROE	32.69%
EPS (TTM)	Rs 7.88
Dividend Yield	0.00%
Debt to Equity	0.34

Compare Pramodini Medicare Against Other Diagnostics and Healthcare Sector Stocks

How Pramodini Medicare Compares Against Its Diagnostics and Healthcare Sector Peers

The table below sets Pramodini Medicare against 2 other Diagnostics and Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Pramodini Medicare	254	14.61	32.69%	0.34
Dr Lal PathLabs	32,511	59.51	20.13%	0.08
Thyrocare Technologies	7,873	44.76	27.85%	0.09
Peer average (2 companies)	-	52.13	23.99%	0.08

Measured against the peer averages, Pramodini Medicare's P/E is 72 percent below the 52.13x average, and its ROE is 8.70 percentage points above the 23.99% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.

What Makes Pramodini Medicare Worth Watching in Diagnostics and Healthcare

• Scale: At Rs 254 Cr, its market capitalisation is smaller than Dr Lal PathLabs (Rs 32,511 Cr) and Thyrocare Technologies (Rs 7,873 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
• Sector drivers: Test volumes through hospital partnerships and its own centres, together with higher value radiology and nuclear medicine services, decide revenue and margins.
• Key risk: Diagnostics needs continuing investment in imaging equipment, and receivables from institutional customers such as hospitals and government bodies can stretch working capital.

Pramodini Medicare Valuation: Is It Justified?

At a P/B ratio of 2.18, the market pays about Rs 2.18 for every rupee of book value, and the EPS (TTM) of Rs 7.88 is the earnings base behind the P/E. The stock trades about 16 percent below its 52-week high and about 5 percent above its 52-week low. The company does not currently show a dividend yield, so returns for shareholders depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Pramodini Medicare and other Diagnostics and Healthcare sector stocks.

How to Track Pramodini Medicare Before You Invest

Before deciding whether Pramodini Medicare deserves its label as the best stock in its sector for your own portfolio, compare it directly against Diagnostics and Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Pramodini Medicare to view live price, valuation ratios, and peer comparisons within the Diagnostics and Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Diagnostics and Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Pramodini Medicare gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Diagnostics and Healthcare depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Pramodini Medicare the best stock in its sector?

Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Pramodini Medicare has a 32.69% ROE and trades at 14.61x P/E against a 59.59x Industry P/E. Against the 2 peers compared in this article, its ROE is above the 23.99% peer average and its P/E is below the 52.13x peer average. Its debt to equity ratio of 0.34 is above the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.

What is the current share price of Pramodini Medicare?

Ans. Pramodini Medicare was trading at Rs 115.10 on the NSE as of 21 October 2026, and its 52-week range runs from Rs 109.50 to Rs 137.00. That leaves the share price 16 percent short of the 52-week high and 5 percent clear of the 52-week low. Its market capitalisation is Rs 254 Cr and its EPS (TTM) is Rs 7.88, which is the earnings figure behind the 14.61x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.

What sector does Pramodini Medicare belong to?

Ans. Pramodini Medicare is classified under the Diagnostics and Healthcare sector on Univest, and that group of listed companies is the reference point for the 59.59x Industry P/E used in this article. The 2 named peers compared here are Dr Lal PathLabs and Thyrocare Technologies, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Diagnostics and Healthcare sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.

How does Pramodini Medicare compare to its sector peers on P/E?

Ans. Pramodini Medicare's P/E of 14.61x is below the 52.13x average of the 2 named peers, with Dr Lal PathLabs at 59.51x and Thyrocare Technologies at 44.76x. It also sits below the 59.59x Industry P/E, which is the benchmark for the wider Diagnostics and Healthcare sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 2.18 gives one more view of how the market values its book value.

What is Pramodini Medicare's return on equity?

Ans. Pramodini Medicare reported a return on equity of 32.69%, which is above the 23.99% average of its named peers, with Dr Lal PathLabs at 20.13% and Thyrocare Technologies at 27.85%. ROE shows how much profit a company generates on every rupee of shareholders' equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.34 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.

Should I invest in Pramodini Medicare based on its sector position?

Ans. Sector position is only one input into an investment decision. Pramodini Medicare has a 32.69% ROE and a 14.61x P/E, which make it worth researching further, and its dividend yield is 0.00%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.